Thursday, January 21, 2010

Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium

THOUSAND OAKS, Calif., Jan 21, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME ‘203’ and ‘181’ trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

Read the rest of this entry

Posted in Press Releases

Wednesday, January 20, 2010

Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results

THOUSAND OAKS, Calif., Jan 20, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Thursday, January 14, 2010

Amgen Donates $2 Million, Establishes Earthquake Relief Program

THOUSAND OAKS, Calif., Jan 14, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq:  AMGN) today announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support.

Read the rest of this entry

Posted in Press Releases

Friday, December 18, 2009

Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union

THOUSAND OAKS, Calif. – Dec 18, 2009 – Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. If approved by the European Commission, Amgen would receive marketing authorization for Prolia in all European Union (EU) Member States.

Read the rest of this entry

Posted in Press Releases

Wednesday, December 16, 2009

Amgen Issues Statement on Update to U.S. Prescribing Information for Erythropoiesis-Stimulating Agents (ESAs)

On December 16, 2009, Amgen updated the boxed warning in the labeling information for the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), to reflect an increased risk of stroke when ESAs are administered to chronic renal failure patients to target hemoglobin levels of 13 g/dL and above. The update was made based on results from the recently completed clinical study, TREAT (the Trial to Reduce Cardiovascular Events with Aranesp Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. In addition, the Warnings section has been updated to include a description of TREAT and the increased risk of stroke found in the study.

Read the rest of this entry

Posted in Company Statements